c-Met/HGFR
Les inhibiteurs de c-Met/HGFR ciblent le Récepteur du Facteur de Croissance des Hépatocytes (c-Met), une tyrosine kinase impliquée dans des processus cellulaires tels que la croissance, la motilité et la morphogenèse. La signalisation de c-Met est impliquée dans la progression du cancer, la métastase et la résistance aux thérapies. Inhiber c-Met peut perturber la croissance et la propagation des tumeurs, faisant de ces inhibiteurs des outils précieux dans la recherche sur le cancer. Chez CymitQuimica, nous proposons des inhibiteurs de c-Met/HGFR pour soutenir vos recherches en oncologie, métastase et thérapies ciblées contre le cancer.
128 produits trouvés pour "c-Met/HGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
PHA-665752
CAS :<p>PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.</p>Formule :C32H34Cl2N4O4SDegré de pureté :97.05% - 98.82%Couleur et forme :SolidMasse moléculaire :641.61Capmatinib
CAS :<p>Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Formule :C23H17FN6ODegré de pureté :99.24%Couleur et forme :SolidMasse moléculaire :412.42PF-04217903
CAS :<p>MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.</p>Formule :C19H16N8ODegré de pureté :98.41% - 98.55%Couleur et forme :SolidMasse moléculaire :372.38SAR125884 hydrochlorid (1116743-46-4(free base))
CAS :<p>SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).</p>Formule :C25H23FN8O2S2·HClDegré de pureté :97.95%Couleur et forme :SolidMasse moléculaire :587JNJ-38877605
CAS :<p>JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.</p>Formule :C19H13F2N7Degré de pureté :97.04% - 98.27%Couleur et forme :SolidMasse moléculaire :377.35Merestinib
CAS :<p>Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.</p>Formule :C30H22F2N6O3Degré de pureté :95% - 99.71%Couleur et forme :SolidMasse moléculaire :552.53MGCD-265 analog
CAS :<p>Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.</p>Formule :C26H20FN5O2S2Degré de pureté :98.06% - 98.68%Couleur et forme :SolidMasse moléculaire :517.6Savolitinib
CAS :<p>Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).</p>Formule :C17H15N9Degré de pureté :98.12%Couleur et forme :SolidMasse moléculaire :345.36Capmatinib xHCl
CAS :<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>Formule :C23H18ClFN6ODegré de pureté :98.62% - 99.81%Couleur et forme :SolidMasse moléculaire :448.89SRI 31215 TFA
CAS :<p>SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.</p>Formule :C27H34F3N5O3Degré de pureté :98.25% - 99.97%Couleur et forme :SolidMasse moléculaire :533.6Cabozantinib
CAS :<p>Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).</p>Formule :C28H24FN3O5Degré de pureté :99.68% - 99.88%Couleur et forme :SolidMasse moléculaire :501.51(Z)-Semaxinib
CAS :<p>(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for</p>Formule :C15H14N2ODegré de pureté :98.82% - ≥95%Couleur et forme :SolidMasse moléculaire :238.28Cabozantinib hydrochloride
CAS :<p>Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6</p>Formule :C28H25ClFN3O5Degré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :537.96BAY-474
CAS :<p>BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe</p>Formule :C17H15N5Degré de pureté :98.98%Couleur et forme :SolidMasse moléculaire :289.33Afatinib
CAS :<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Formule :C24H25ClFN5O3Degré de pureté :98.56% - 99.9%Couleur et forme :Off-White SolidMasse moléculaire :485.94Amivantamab
CAS :<p>Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.</p>Degré de pureté :97.24% (SEC-HPLC) - 99.74%Couleur et forme :LiquidMasse moléculaire :145.88 kDaFiclatuzumab
CAS :<p>Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.</p>Degré de pureté :95%Couleur et forme :LiquidDavutamig
CAS :<p>Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.</p>Degré de pureté :98%Couleur et forme :LiquidBafisontamab
CAS :<p>Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].</p>Couleur et forme :LiquidMAPK-IN-2
<p>MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell</p>Formule :C20H11Cl2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.23
